Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $2.06, $0.12 better than the analyst estimate of $1.94. Revenue for the quarter came in at $995.8 million versus the consensus estimate of $978.34 million.

GUIDANCE:

Charles River Laboratories sees FY 2026 EPS of $10.80-$11.30, versus the consensus of $11.07.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.